Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

R. Tawil; J. Han; L. Wang; J. Vissing; B. van Engelen; J. Statland; M. Mellion; J. Shoskes; C. Morabito; J. Jiang; J. Webster

doi:10.1016/j.nmd.2022.07.258

Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

R. Tawil
, J. Han
, L. Wang
, J. Vissing
, B. van Engelen
, J. Statland
, M. Mellion
, J. Shoskes
, C. Morabito
, J. Jiang
, J. Webster

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	P.136
Tidsskrift	Neuromuscular Disorders
Vol/bind	32
Udgave nummer	Supplement 1
Sider (fra-til)	S104-S104
Antal sider	1
ISSN	0960-8966
DOI	https://doi.org/10.1016/j.nmd.2022.07.258
Status	Udgivet - 2022
Begivenhed	27th International Congress of the World-Muscle-Society (WMS) - Halifax, Canada Varighed: 11 okt. 2022 → 15 okt. 2022

Konference

Konference	27th International Congress of the World-Muscle-Society (WMS)
Land/Område	Canada
By	Halifax
Periode	11/10/2022 → 15/10/2022

Adgang til dokumentet

10.1016/j.nmd.2022.07.258

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Tawil, R., Han, J., Wang, L., Vissing, J., van Engelen, B., Statland, J., Mellion, M., Shoskes, J., Morabito, C., Jiang, J., & Webster, J. (2022). Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD. Neuromuscular Disorders, 32(Supplement 1), S104-S104. Artikel P.136 . https://doi.org/10.1016/j.nmd.2022.07.258

Tawil, R, Han, J, Wang, L, Vissing, J, van Engelen, B, Statland, J, Mellion, M, Shoskes, J, Morabito, C, Jiang, J & Webster, J 2022, 'Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD', Neuromuscular Disorders, bind 32, nr. Supplement 1, P.136 , s. S104-S104. https://doi.org/10.1016/j.nmd.2022.07.258

@article{9cb316a3db884cf5b7dcddf6a1804daa,

title = "Design of Reach: Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD",

author = "R. Tawil and J. Han and L. Wang and J. Vissing and \{van Engelen\}, B. and J. Statland and M. Mellion and J. Shoskes and C. Morabito and J. Jiang and J. Webster",

year = "2022",

doi = "10.1016/j.nmd.2022.07.258",

language = "English",

volume = "32",

pages = "S104--S104",

journal = "Neuromuscular Disorders",

issn = "0960-8966",

publisher = "Elsevier",

number = "Supplement 1",

note = "27th International Congress of the World-Muscle-Society (WMS) ; Conference date: 11-10-2022 Through 15-10-2022",

}

TY - ABST

T1 - Design of Reach

T2 - 27th International Congress of the World-Muscle-Society (WMS)

AU - Tawil, R.

AU - Han, J.

AU - Wang, L.

AU - Vissing, J.

AU - van Engelen, B.

AU - Statland, J.

AU - Mellion, M.

AU - Shoskes, J.

AU - Morabito, C.

AU - Jiang, J.

AU - Webster, J.

PY - 2022

Y1 - 2022

U2 - 10.1016/j.nmd.2022.07.258

DO - 10.1016/j.nmd.2022.07.258

M3 - Conference abstract in journal

SN - 0960-8966

VL - 32

SP - S104-S104

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

IS - Supplement 1

M1 - P.136

Y2 - 11 October 2022 through 15 October 2022

ER -